INVESTMENT STRATEGY
Where We Deploy Capital
Two decades operating inside the regulated substance markets now transforming behavioral health. We deploy capital where conventional PE lacks the expertise to compete and most healthcare funds have yet to reach.
This Is Not a Consulting Problem.
Behavioral health has an infrastructure gap. The regulated substances categories driving its transformation — cannabis, psychedelics, the therapies emerging from both — sit at an intersection that generalist PE cannot navigate and traditional healthcare funds have not yet reached. Capital has entered these markets before and failed. Not because the timing was wrong. Because the expertise wasn’t there. These categories don’t need better advice. They need an operator-led GP with the regulatory fluency, clinical build experience, and network access to acquire the right assets and execute toward a real outcome. That is what SIVA Capital is built to do.
Operator Knowledge
Over two decades operating inside cannabis, not just observing it. We’ve occupied every seat at the table — from operator and advisor to regulator-facing executive. That range is not a résumé point — it is the difference between knowing how these markets work and knowing how to work them. We know where the levers are, which ones to pull, and how to pull them.
Capital Formation
Prior capital consistently mismanaged these markets. The failure was never timing — it was stewardship. Cannabis and psychedelics demand regulatory fluency and operational depth that generalist funds do not have. SIVA Capital closes that gap: operator-led, LP-aligned, deploying the expertise prior funds lacked.
Distressed Assets
Cannabis assets trade at dislocated prices — not because the underlying value is impaired, but because the businesses are. We source through relationships and negotiated transactions built over two decades — deals outside capital cannot identify, reach, or execute.
OUR PHILOSOPHY
An Operator's Approach to Capital Allocation
We believe value in these markets is not engineered through financial leverage — it is earned through operational improvement. Our philosophy starts there: understand the asset the way an operator would before you price it the way an investor would.
Returns are earned,
not engineered
We acquire businesses where operational improvements drive value — not financial leverage applied to a distressed balance sheet. We don't treat these as single vertical industries, we treat them as dynamic ecosystems with different levers to pull. Financial statements tell you where a business stands. We know why it got there — and what it takes to change it.
Conviction over
deal flow
We only deploy capital where we have genuine conviction — and conviction in these markets requires more than a thesis. It requires understanding the industry from the inside: the relationship between sectors and operators, the supply chain, the needs of the end consumer, and the economics that generalists consistently misread. We do not chase deal flow. We invest where our knowledge and experience create an edge that outside capital cannot replicate.
“The key to Private Equity is next year’s ideas…even if your record is built on last year’s ideas.”
— Jim Coulter, Co-Founder, TPG
FOCUS AREAS
Our Investment Thesis
Behavioral health is the defining healthcare challenge of this decade. The regulated substance categories emerging to address it — cannabis and psychedelics — have followed different paths to this moment. Cannabis built through state regulation. Psychedelics built through clinical validation. Both are arriving at scale simultaneously. Most capital understands neither, while we built our track record on it. We take control positions — operational, financial, and board — because the gap between where these businesses are and what they could be isn’t closed by capital alone. It’s closed by operators who’ve been inside these markets.
01 — Cannabis
The Foundation
Cannabis didn’t fail the market. The model failed cannabis. Operators built commodity businesses, mistook scale for strategy, and ran the license as if it was the business. SIVA targets these operators at distressed valuations and rebuilds around a fundamentally different premise. Simple in concept. Significant in execution. We’re not in the cannabis business. We’re in the business that cannabis licenses make possible. The license is the entry point. Everything else is the business.
02 — Psychedelics
The Forward Position
Psychedelics is not a single market. It’s a platform — one license, multiple therapeutic categories, multiple distribution channels, and exit paths that lead into mainstream healthcare, not back into the psychedelics sector. The industry sees a wellness category. We see a healthcare infrastructure play.
SIVA enters at the clinical-to-commercial transition with a thesis built around how these compounds will actually be distributed — not how they’re currently being sold. The addressable market is larger than most recognize — not because the data is hidden, but because most analysis stops at the compound and never reaches the delivery infrastructure.
Investment Criteria
How We Select
01
Control First
We target operational, financial, and board control. We don't write passive checks.
02
Distressed Entry
Compressed valuations in high-demand regulated markets. Consumer scale, not license scarcity, drives the return.
03
Defensible License
Viable regulatory position and compliance infrastructure that justifies the entry price.
04
Execution-Fixable
Management failure, not market failure. Operators that ran the wrong model on a viable asset.
Why Now
The cannabis industry spent a decade proving what doesn't work. That is the most valuable thing it could have done.
Cannabis investors have heard "now is the time" since 2015. This is different — the correction is complete. Capital is out. Valuations reflect actual distress. Regulatory frameworks have matured. In 2 to 3 years, capital returns and prices normalize. The entry window is a present market condition, not a projection.
Psychedelics presents a different picture. Clinical validation is further along than most assume. Institutional capital is already active — on the research and drug development side. What does not yet exist is the operational and service delivery infrastructure required to bring these therapies to patients at scale. The window to build operating infrastructure before institutional capital prices it in is open now. It will not stay open.
SIVA was not built for a generic PE moment. The operator relationships, regulatory navigation, and knowledge base were built from within and across for more than 20 years — at the exact inflection points now defining the opportunity. That expertise does not transfer to another fund. The moment it was built for is this one.
Ready to Start the Conversation?
If you are a family office, institutional investor, strategic partner, or operator exploring capital options, we want to hear from you.